Intended Audience: Healthcare Professionals including Obstetricians, Gynecologists, Physician Assistants, and Nurses specializing in Women's Health (NPs, APNs, CMs, and RNs); Primary Care Physicians and Family Medicine Practitioners
Bayer TA Rationale for Educational Support:
- Educate health care professionals on the broad impact of menopause on women in both their personal and professional lives, including physical, emotional, and financial effects.
- Provide guidance on the identification, counseling, and management of women as they enter the menopausal transition.
- Expand awareness of the role of the hypothalamic KNDy system on vasomotor symptoms, sleep disorders, and mood disturbances.
- Downloadable slides
- Incorporation of social media outreach (You-Tube, FaceBook, Spotify, LinkedIn, Twitter)
- Live Virtual
The proposal must be compliant with standards and guidelines for commercial support (e.g., ACCME).
The proposal should include:
- Needs assessment
- Educational design and rationale for selection (where applicable)
- Learning Objectives
- Proposed Faculty
- Participant recruitment plan (where applicable)
- Outcomes strategy/plan
- Detailed budget (please use the template available on the website)
Copy of most recent accreditation letter and status
Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.
Acceptance of a Bayer educational grant indicates that you will:
- Reconcile grant funding within 60 days of completion of the educational program
- Permit a Bayer Medical Affairs representative to audit live programs
- Share activity data and outcomes metrics within 30 days of their availability
- Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health qual Life Outcomes 2005;3:47.
- Whiteley J, et al. The impact of menopausal symptoms on quality of life, productivity, and economic outcomes. J of Women’s Health 2013:22:983.
- Dominus S. Women have been misled about menopause. New York times. Published Feb 1, 2023.
- United States Census Bureau. Population estimates (sex by age), 2008.
- Hill K. The demography of menopause. Maturatas 1996;23:113.
- Nappi RE, Kroll R, Siddiqui E, et al. Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden. Menopause 2021;28:875.
- Thurston RC, Chang Y, Buysse DJ, et al. Hot flashes and awakenings among midlife women. Sleep 2019;42:zsz131.
- Williams RE, Kalilani L, Britt Dibenedtti D, et al. Frequency and severity of vasomotor symptoms among peri-and postmenopausal women in the United States. Climacteric 2008;11:32.
- Freeman EW, Sammel MD, Lin H, et al. Duration of menopausal hot flushes and associated risk factors. Obstet Gynecol 2011;117::1095.
- Woods NF , Hohensee C, Carpenter JS, et al. Symptom clusters among MsFLASH clinical trial participants. Menopause 2016;23:158.
- NAMS Position Statement: The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022;29:767.
- ACOG Practice Bulletin: Management of menopausal symptoms. Number 141, Jan 2014 (reaffirmed 2018).
- Crawford SL, Crandall CJ, Derby CA, et al. Menopausal hormone therapy trends before versus after 2002: impact of the Women’s Health Initiative study results. Menopause 2018;26:588.
- Optum Claims Data 2020: US VMS Patient Market Landscape, accessed January 2023.
- Biglia N, Bounous VE, De Seta F, et al. Non-hormonal strategies for managing menopausal symptoms in cancer survivors: an update. Ecancermedicalscience 2019;13:909.
- Orleans RJ, Li L, Kim M-J, et al. FDA approval of paroxetine for menopausal hot flushes. N Engl J Med 2014;370:1777.
- Bayer Data on File. Source Symphony Health. Accessed April 2023.
- Rance NE, Dacks PA, Mittleman-Smith MA, et al. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol 2013;34:211.
- Rance NE, Young WS 3rd. Hypertrophy and increased gene expression of neurons containing neurokinin-B and substance-P messenger ribonucleic acids in the hypothalamus of postmenopausal women. Endocrinology 1991;128:2239.
- Padilla SL, Johnson CW, Barker FD, et al. A neuronal circuit underlying the generation of hot flushes. Cell Rep 2018;24:271.
- Hrabovszky E, Borsay BA, Racz K, et al. Substance P immunoreactivity exhibits frequent colocalization with kisspeptin and neurokinin B in the human infundibular region. PLoS One 2013;8:e72369.
- Lieb K, Ahlvers K, Dancker K, et al. Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men. Neuropsychopharmacology 2002;27:1041.
- Simon JA, Anderson RA, Ballantyne E, et al. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). Menopause 2023;30:239.
- Modi M and Dhillo WS. Neurokinin B and Neurokinin-3 receptor signaling: promising developments in the management of menopausal hot flushes. Semin Reprod Med 2019;37:125.
- Christianson MS, Ducie JA, Altman K, et al. Menopause education: needs assessment of American obstetrics and gynecology residents. Menopause 2013:20:1120.
- Richard-Davis G, Singer A, King DD, Mattle L. Understanding attitudes, beliefs, and behaviors surrounding menopause transition:results from three surveys. Patient Related Outcome Measures 2022:13:273.